Neos Therapeutics, Inc. Sustainability Profile
Neos Therapeutics, Inc., a prominent player in the pharmaceutical industry, is headquartered in the United States. Founded in 2006, the company has made significant strides in developing innovative treatments for attention deficit hyperactivity disorder (ADHD) and other central nervous system disorders. Neos is particularly known for its unique extended-release formulations, which enhance patient compliance and therapeutic outcomes. With a focus on delivering high-quality, effective medications, Neos Therapeutics has established a strong market position, recognised for its commitment to research and development. The company’s flagship products, including Adzenys XR-ODT and Cotempla XR-ODT, stand out for their distinctive delivery systems, offering patients convenient and effective treatment options. Through its dedication to advancing ADHD therapies, Neos continues to make a meaningful impact in the lives of patients and healthcare providers alike.
DitchCarbon Score
How does Neos Therapeutics, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Neos Therapeutics, Inc.'s score of 25 is lower than 56% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Neos Therapeutics, Inc.'s reported carbon emissions
Neos Therapeutics, Inc., headquartered in the US, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. The company has not established any documented reduction targets or climate pledges, which suggests a lack of formal commitments to reducing its carbon footprint at this time. However, it is important to note that Neos Therapeutics, Inc. is a current subsidiary of Aytu BioPharma, Inc. This relationship may imply that any future emissions data or climate initiatives could be influenced by the parent company's strategies and commitments. As of now, there are no specific emissions figures or reduction initiatives reported from either Neos Therapeutics or Aytu BioPharma. In summary, while Neos Therapeutics has not disclosed any emissions data or climate commitments, its affiliation with Aytu BioPharma may provide a pathway for future climate action and reporting.
How Carbon Intensive is Neos Therapeutics, Inc.'s Industry?
How Carbon Intensive is Neos Therapeutics, Inc.'s Location?
Neos Therapeutics, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Neos Therapeutics, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
